id:"swepub:oai:lup.lub.lu.se:07b34109-c90a-46f7-bd88-48c0a452baaa"
Search: id:"swepub:oai:lup.lub.lu.se:07b34109-c90a-46f7-bd88-48c0a452baaa" > Multicentre phase I...
- 1 of 1
- Previous record
- Next record
- To hitlist
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04360naa a2200469 4500 | |
| 001 | oai:lup.lub.lu.se:07b34109-c90a-46f7-bd88-48c0a452baaa | |
| 003 | SwePub | |
| 008 | 160401s2010 | |||||||||||000 ||eng| | |
| 009 | oai:DiVA.org:uu-125793 | |
| 009 | oai:prod.swepub.kib.ki.se:120906628 | |
| 024 | 7 | a https://lup.lub.lu.se/record/16294532 URI |
| 024 | 7 | a https://doi.org/10.1016/j.radonc.2010.04.0042 DOI |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1257932 URI |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1209066282 URI |
| 040 | a (SwePub)lud (SwePub)uud (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a art2 swepub-publicationtype |
| 072 | 7 | a ref2 swepub-contenttype |
| 100 | 1 | a Gunnlaugsson, Adalsteinnu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-agg |
| 245 | 1 0 | a Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study |
| 264 | 1 | b Elsevier BV,c 2010 |
| 520 | a Background and Purpose: In this multicentre phase I-II trial we evaluated the feasibility and efficacy of capecitabine and oxaliplatin followed by the combination of these two drugs with radiotherapy in patients with locally advanced pancreatic or biliary tract cancer. Material and methods: Thirty-nine patients with inextirpable adenocarcinoma of the pancreas, gallbladder or extrahepatic bile ducts were included. Two cycles of XELOX (capecitabine 1000 mg/m(2) bid d1-14 + oxaliplatin 130 mg/m(2) d1, q3w) were followed by XELOX-RT (radiotherapy (50.4 Gy), combined with capecitabine 750-675 mg/m(2) bid every radiotherapy day and oxaliplatin 40-30 mg/m(2) once weekly). Primary end-points were tolerance (phase I) and objective response (phase II). Results: The maximum tolerated doses of oxaliplatin and capecitabine to combine with irradiation were 30 mg/m(2) and 675 mg/m(2), respectively. Twenty-one percent (95% CI: 9-38%) of evaluable patients achieved partial response. Five patients went through surgery (three R0 resections). Two-year survival was 28%, and estimated local tumour control rate at 2 years was 72%. The most common grade 3-4 toxicity was nausea and vomiting. Conclusions: XELOX-RT (30 mg/m(2) oxaliplatin/675 mg/m(2) capecitabine in combination with 50.4 Gy/28 fractions) was well tolerated and effective for locally advanced pancreatic and biliary tract cancer. (C) 2010 Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 95 (2010) 292-297 | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
| 653 | a Pancreatic cancer | |
| 653 | a Oxaliplatin | |
| 653 | a Biliary tract cancer | |
| 653 | a Capecitabine | |
| 653 | a Radiotherapy | |
| 653 | a MEDICINE | |
| 700 | 1 | a Anderson, Haraldu Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-han |
| 700 | 1 | a Lind, Pehru Karolinska Institutet4 aut |
| 700 | 1 | a Glimelius, Bengtu Karolinska Institutet,Uppsala universitet,Enheten för onkologi4 aut0 (Swepub:uu)bengglim |
| 700 | 1 | a Johnsson, Andersu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-ajo |
| 710 | 2 | a Bröstcancer-genetikb Sektion I4 org |
| 773 | 0 | t Radiotherapy and Oncologyd : Elsevier BVg 95:3, s. 292-297q 95:3<292-297x 1879-0887x 0167-8140 |
| 856 | 4 | u http://dx.doi.org/10.1016/j.radonc.2010.04.004y FULLTEXT |
| 856 | 4 8 | u https://lup.lub.lu.se/record/1629453 |
| 856 | 4 8 | u https://doi.org/10.1016/j.radonc.2010.04.004 |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-125793 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:120906628 |
Find in a library
- Radiotherapy and Oncology (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Gunnlaugsson, Ad ...
- Anderson, Harald
- Lind, Pehr
- Glimelius, Bengt
- Johnsson, Anders
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Radiotherapy and ...
- By the university
- Lund University
- Uppsala University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
